Search
T cell receptor beta variable 6-5
go.drugbank.com/bio_entities/BE0021562TargetHumansV region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447).
Polypeptides: T cell receptor beta variable 6-5Palmitic Acid
go.drugbank.com/drugs/DB03796ApprovedInvestigationalA common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.
Mixtures: Jayjun Real Water Shining Cleansing Foa M, Jayjun Real Water Shining Vita Cleansing Foa MLatanoprostene bunod
go.drugbank.com/drugs/DB11660ApprovedAs of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma
Fostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically … [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalEach subunit is glycosylated with high-mannose-type glycans [FDA Label]. … Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label].
Moxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnMoxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, AC...
Categories: Imidazoline Receptor Agonists, Adrenergic alpha-2 Receptor AgonistsVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755] … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalXIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation cascade [FDA … is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency [FDA